Request appointment
10 E 102nd StNew York, NY 10029
Fax+1 212-423-0522
Overview of Dr. Galsky
Dr. Matthew Galsky is an oncologist in New York, NY and is affiliated with The Mount Sinai Hospital. He received his medical degree from Tufts University School of Medicine and has been in practice 28 years. Dr. Galsky accepts several types of health insurance, listed below. He is one of 187 doctors at The Mount Sinai Hospital who specialize in Oncology. He has more than 100 publications and over 500 citings.
Education & Training
Memorial Sloan Kettering Cancer CenterFellowship, Hematology and Medical Oncology, 2001 - 2004
Beth Israel Deaconess Medical CenterResidency, Internal Medicine, 1998 - 2001
Tufts University School of MedicineClass of 1998
Certifications & Licensure
NY State Medical License 2001 - 2027
NV State Medical License 2006 - 2011
American Board of Internal Medicine Medical Oncology
Clinical Trials
Publications & Presentations
PubMed
- Phase II Randomized Trial of Radium-223 Dichloride and Cabozantinib in Patients With Renal Cell Carcinoma With Bone Metastases: RADICAL (Alliance A031801).Rana R McKay, Karla V Ballman, Pamela J Atherton, Archana Ajmera, Tareq Al Baghdadi
Journal of Clinical Oncology. 2026-08-20 - Cystectomy Can Be Spared in Selected Patients with Muscle-invasive Bladder Cancer and Complete Response Following Neoadjuvant Therapy.Matthew D Galsky, Andrea Necchi
European Urology. 2026-07-27 - Enfortumab Vedotin and Pembrolizumab in Cisplatin-Eligible Bladder Cancer.Matthew D Galsky, Begoña P Valderrama, Marco Maruzzo, Albert Font, Tudor Ciuleanu
The New England Journal of Medicine. 2026-07-23
Journal Articles
- Identification of microR-106b as a Prognostic Biomarker of p53-like Bladder Cancers by ActMiRMatthew D Galsky, William K Oh, Nature
Lectures
- A phase III, randomized, open label, multicenter, global study of first-line (1L) durvalumab in combination with standard of care (SOC) chemotherapy and durvalumab in ...2019 ASCO Annual Meeting - 6/1/2019
- Randomized double-blind phase II study of maintenance pembrolizumab versus placebo after first-line chemotherapy in patients (pts) with metastatic urothelial cancer (m...2019 ASCO Annual Meeting - 6/1/2019
- Is there a difference in PD-1 / PD-L1 inhibitors for urothelial cancer? Continuous Evolution of a Phase I Trial Into An FDA Package2018 ASCO Annual Meeting - Chicago, Illinois - 05/31/2018
Authored Content
- Gemcitabine, Cisplatin, and Nivolumab with Selective Bladder Sparing in MIBC: Co-Primary Endpoint Analysis of HCRN GU 16-256 Phase II Trial - Matthew GalskyApril 2023
- PD-1/PD-L1 Inhibition in Bladder Cancer Now and in the Future, Part 1March 2023
Press Mentions
Matthew D. Galsky, MD, FASCO, on Muscle-Invasive Bladder Cancer: Enfortumab Vedotin and PembrolizumabMarch 9th, 2026- Perioperative Enfortumab Vedotin Plus Pembro Outperforms Chemo in Muscle-Invasive Bladder CancerMarch 2nd, 2026
- Periop Enfortumab Vedotin Plus Pembrolizumab Shows Strong Efficacy in Cisplatin-Eligible MIBCMarch 2nd, 2026
Grant Support
- Dissecting myeloid cell-mediated resistance to immune checkpoint blockade in bladder cancerICAHN SCHOOL OF MEDICINE AT MOUNT SINAI2020–2025
- Dissecting myeloid cell-mediated resistance to immune checkpoint blockade in bladder cancerICAHN SCHOOL OF MEDICINE AT MOUNT SINAI2020–2025
Insurance Accepted
- Aetna Choice POS II
Aetna HMO
BCBS Blue Card PPO
CIGNA HMO
CIGNA Open Access
CIGNA PPO
Empire BCBS HMO
Empire BCBS PPO
First Health PPO
GHI PPO
Great West PPOHIP of New York - Select PPO
Humana ChoiceCare Network PPO
MagnaCare PPO
Multiplan PHCS PPO
Multiplan PPO
MVP Healthcare PPO
Oxford Health Freedom
Oxford Health Liberty
United Healthcare - Direct Choice Plus POS
United Healthcare - Direct Options PPO - Please verify your coverage with the provider's office directly when scheduling an appointment
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
